Profile nucleases and Repurpose Off-Targets to Expand Gene Editing

The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.

Subsidie
€ 1.141.779
2023

Projectdetails

Introduction

Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, relies on a guide RNA (gRNA) – its program – to precisely cut a complementary genetic sequence – its target – for precision gene editing.

Applications of Programmable Nucleases

These programmable nucleases deliver cures for genetic diseases like:

  1. Anemia
  2. Blindness
  3. Cancer

They also facilitate quick disease model development and diagnostics for viruses like SARS-CoV-2.

Discovery of Nucleases

Hunts across microbial genomes have exposed thousands of programmable nucleases. Each could be another valuable tool for genome engineers, but we know just too little about them to use them safely.

Challenges with Off-Target Effects

Even Cas9 does not have guide-target parity: It cuts partially matched ‘off-target’ genome sites, which can lead to dangerous side effects. Though we work hard to avoid off-targets, partial matching may have a bright side.

Research Hypothesis

What if we leverage it, using it to make gene editing more predictable? Using high-throughput biochemistry, we will Profile nucleases and Repurpose Off-Targets to Expand Gene Editing.

The PROTÉGÉ Research Program

The PROTÉGÉ research program will:

  • Profile guide-target parity – specificity – across promising, newly discovered programmable nucleases.
  • Deliver a toolset for assessing this critical safety feature rapidly and broadly.
  • Test the hypothesis that purposefully misprogramming nucleases can direct specific repair outcomes.

Conclusion

We intend to benefit Europe and the world community with safer and more diverse gene editing tools for achieving its Horizon Europe health, technology, and environmental goals.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.141.779
Totale projectbegroting€ 1.141.779

Tijdlijn

Startdatum1-6-2023
Einddatum31-5-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • VILNIAUS UNIVERSITETASpenvoerder

Land(en)

Lithuania

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.

€ 150.000
ERC Starting...

Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificities

EditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases.

€ 1.599.500
ERC Consolid...

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

€ 2.249.895
ERC Advanced...

Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells

INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.

€ 2.475.491
ERC Starting...

Molecular mechanisms, functions and applications of RNA-guided DNA transposons

This project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine.

€ 1.499.403

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

€ 4.406.097
EIC Accelerator

Next generation gene writing platform to cure genetic and oncological diseases

Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.

€ 2.496.375
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
Mkb-innovati...

FluEdit: Microfluidics Gen-editing platform voor bloedcellen

NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.

€ 20.000
EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

€ 2.998.878